Phathom Pharmaceuticals (PHAT) Debt to Equity (2022 - 2025)
Historic Debt to Equity for Phathom Pharmaceuticals (PHAT) over the last 4 years, with Q3 2025 value amounting to -$0.49.
- Phathom Pharmaceuticals' Debt to Equity rose 4781.3% to -$0.49 in Q3 2025 from the same period last year, while for Sep 2025 it was -$0.49, marking a year-over-year increase of 4781.3%. This contributed to the annual value of -$0.79 for FY2024, which is 5807.54% up from last year.
- According to the latest figures from Q3 2025, Phathom Pharmaceuticals' Debt to Equity is -$0.49, which was up 4781.3% from -$0.51 recorded in Q2 2025.
- Over the past 5 years, Phathom Pharmaceuticals' Debt to Equity peaked at $5.56 during Q2 2023, and registered a low of -$13.2 during Q2 2022.
- Over the past 4 years, Phathom Pharmaceuticals' median Debt to Equity value was -$0.94 (recorded in 2024), while the average stood at -$1.58.
- Within the past 5 years, the most significant YoY rise in Phathom Pharmaceuticals' Debt to Equity was 14208.51% (2023), while the steepest drop was 14476.42% (2023).
- Quarter analysis of 4 years shows Phathom Pharmaceuticals' Debt to Equity stood at -$1.27 in 2022, then plummeted by 48.78% to -$1.89 in 2023, then soared by 58.08% to -$0.79 in 2024, then soared by 38.29% to -$0.49 in 2025.
- Its Debt to Equity stands at -$0.49 for Q3 2025, versus -$0.51 for Q2 2025 and -$0.6 for Q1 2025.